Research programme: Mena protein isoforms therapeutics - MetaStat

Drug Profile

Research programme: Mena protein isoforms therapeutics - MetaStat

Alternative Names: Mena isoform proteins

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MetaStat Inc
  • Class Antibodies; Antineoplastics; Diagnostic agents; Monoclonal antibodies; Peptides; Small molecules
  • Mechanism of Action Actin modulators; MAP-kinase-activated kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 22 Jun 2018 Pharmacodynamics data from a preclinical study released by MetaStat
  • 22 Aug 2017 MetaStat has four patent protection and allowance of claims in the US, and three international patents for the core Mena protein technology (MeStat website, August 2017)
  • 11 Aug 2017 Preclinical trials in Cancer in USA (unspecified route) (MetaStat pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top